Cerus Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Concord CA United States (2003)
Status: No NME R&D (2003)

Organization Overview

First Clinical Trial
2012
NCT01711346
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cerus Corporation

Active Ingredients

Drugs in Phase 4 Trials (2)

crystalloid (1 trial)

pathogen-reduced plasma (1 trial)

Drugs in Phase 3 Trials (2)

red blood cells (3 trials)

s303 red blood cells (3 trials)

Drugs in Phase 2 Trials (1)

intercept platelets (2 trials)

Drugs in Phase 1 Trials (1)

intercept plasma (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

beta-Thalassemia (Phase 3)

Hemorrhagic Fever, Ebola (Phase 1)

Lung Injury (Phase 4)

Thalassemia (Phase 3)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 6